Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ418MR)

This product GTTS-WQ418MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ418MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12428MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NI-0501
GTTS-WQ11128MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ3605MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ534MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 4D11
GTTS-WQ1067MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ABBV-838
GTTS-WQ5724MR IVTScrip™ mRNA-Anti-CEACAM5, CEA-IL-2v(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CEA-IL-2v
GTTS-WQ536MR IVTScrip™ mRNA-Anti-CD40, 4D11(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 4D11
GTTS-WQ13247MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA PF-05335810
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW